Pages that link to "Q38326593"
Jump to navigation
Jump to search
The following pages link to Danny Liew (Q38326593):
Displaying 50 items.
- Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis (Q24242787) (← links)
- Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70 (Q28175859) (← links)
- Utility of B-type natriuretic peptide as a screen for left ventricular dysfunction in patients with diabetes: response to Epshteyn et al (Q28247204) (← links)
- Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003 (Q28281037) (← links)
- The Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platform (Q28488248) (← links)
- N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study (Q30463476) (← links)
- Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol (Q30490484) (← links)
- The impact of lost therapeutic benefit (LTB) in high-risk hypertensive patients: 2-year follow-up data from the Australian REACH registry. (Q30615846) (← links)
- Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data (Q30619855) (← links)
- Predictors of health care use among patients with or at high risk of atherothrombotic disease: two-year follow-up data (Q30818646) (← links)
- The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis (Q33420117) (← links)
- Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry (Q33545383) (← links)
- Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions (Q33578364) (← links)
- An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol (Q33680901) (← links)
- Cost-benefit of minimally invasive staging of non-small cell lung cancer: a decision tree sensitivity analysis. (Q33703632) (← links)
- Estimating the lifetime economic burden of stroke according to the age of onset in South Korea: a cost of illness study (Q33992080) (← links)
- Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort. (Q34007717) (← links)
- Cost-effectiveness of optimizing use of statins in Australia: using outpatient data from the REACH Registry (Q34044093) (← links)
- Radial probe EBUS versus CT-guided needle biopsy for evaluation of peripheral pulmonary lesions: an economic analysis (Q34353015) (← links)
- A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. (Q34620274) (← links)
- The "cost" of treating to target: cross-sectional analysis of patients with poorly controlled type 2 diabetes in Australian general practice (Q34627590) (← links)
- The role of aldosterone receptor blockade in the management of cardiovascular disease (Q34996486) (← links)
- Evaluating the effects of increasing physical activity to optimize rehabilitation outcomes in hospitalized older adults (MOVE Trial): study protocol for a randomized controlled trial (Q34998773) (← links)
- Novel biomedical risk markers for cardiovascular disease (Q35060390) (← links)
- Should patients with chronic heart failure be treated with "statins"? (Q35084619) (← links)
- New developments in the pharmacological treatment of chronic heart failure (Q35117060) (← links)
- Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. (Q35126357) (← links)
- Eplerenone. Pharmacia (Q35126361) (← links)
- Aldosterone receptor antagonists for hypertension: what do they offer? (Q35214540) (← links)
- Emergency department length of stay independently predicts excess inpatient length of stay (Q35580504) (← links)
- New and emerging drug therapies for the management of acute heart failure. (Q35600523) (← links)
- Predictors of disability worsening in clinically isolated syndrome. (Q35619185) (← links)
- Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study (Q35629002) (← links)
- Cardiovascular effects of selective cyclooxygenase-2 inhibitors (Q35777371) (← links)
- Eplerenone in the treatment of chronic heart failure. (Q35777385) (← links)
- Benefits and resource implications of family meetings for hospitalized palliative care patients: research protocol (Q35865661) (← links)
- Potential cardiovascular consequences of switching from atorvastatin to generic simvastatin in the Netherlands. (Q35942147) (← links)
- The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model (Q36001140) (← links)
- Blood pressure effects of COX-2 inhibitors. (Q36512092) (← links)
- Current and emerging antiviral treatments for hepatitis C infection (Q36729900) (← links)
- Overview of pharmacoeconomic modelling methods (Q36729904) (← links)
- Cost-effectiveness of Crohn's disease post-operative care (Q36747868) (← links)
- Diabetes prevention and treatment strategies: are we doing enough? (Q37106518) (← links)
- Effectiveness of general practice based, practice nurse led telephone coaching on glycaemic control of type 2 diabetes: the Patient Engagement and Coaching for Health (PEACH) pragmatic cluster randomised controlled trial (Q37181434) (← links)
- Predicting the effectiveness of prevention: a role for epidemiological modeling (Q37200657) (← links)
- Potential survival gains in the treatment of myocardial infarction. (Q37576786) (← links)
- Drug treatment and cost of cardiovascular disease in Australia. (Q37581979) (← links)
- Can primary care team-based transition to insulin improve outcomes in adults with type 2 diabetes: the stepping up to insulin cluster randomized controlled trial protocol (Q37595875) (← links)
- Inequalities in cardiovascular disease mortality: the role of behavioural, physiological and social risk factors (Q37614053) (← links)
- Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea (Q37634716) (← links)